Choosing Wisely in pathology
Choosing Wisely in pathology
Latest in PARP inhibitors and combination therapies for prostate cancer
3 year follow-up of the CheckMate 9ER trial: NIVO + cabozantinib vs sunitinib for first-line treatment of aRCC
Plasma miR371 detects MRD and early relapse of germ cell tumours
Cabozantinib after checkpoint inhibitors demonstrates preliminary efficacy in advanced RCC
Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC
Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in subset of muscle-invasive bladder cancer patients
Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial carcinoma after radical resection
Hypofractionated high dose intensity modulated radiotherapy non-inferior for prostate cancer
JAVELIN Bladder 100: Avelumab maintenance indicated as a standard of care for advanced urothelial carcinoma
Safety and efficacy of immune checkpoint inhibitors in advanced penile squamous cell carcinoma
HER2DX: a new diagnostic tool for early-stage HER2 positive breast cancer